---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-063316"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-09-24T11:05:32+00:00"
generated_at: "2026-09-24T11:35:21.987851+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports positive fasedienol data in very severe social anxiety at Psych Congress 2026

## Summary
- Post-hoc PALISADE-4 Phase 3 analysis showed statistically significant SUDS improvement in very severe SAD (LSAS >=95) despite missed primary endpoint in overall population.
- Phase 2a repeat-dose study prespecified analysis: significant SUDS improvement after single dose; greater numerical improvement after second dose taken 10 minutes later.
- Second-dose data also showed significant improvements in anticipatory anxiety pre-PSC in both overall and very severe populations.
- Safety in very severe subgroup consistent with prior trials; no serious drug-related signals identified.
- Data presented at Psych Congress 2026 in New Orleans; supports fasedienol's potential for LSAS >=95 patients.

## SEC filing metadata
- accession: 0001628280-26-063316
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-09-24T11:05:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/0001628280-26-063316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/vtgn-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-063316
- JSON: https://secwatch.observer/filing/0001628280-26-063316.json
- Plain text: https://secwatch.observer/filing/0001628280-26-063316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.